Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287491 | 0.84 | CLK1 (0.47) | CLK1KDM4EALDH1A1HPGDPKM | |
| SCHEMBL6289000 | 0.81 | CLK1 (0.45) | CLK1KDM4EALDH1A1HPGDPKM | |
| SCHEMBL6279723 | 0.80 | RXFP1 (0.57) | ALDH1A1RXFP1NPC1RAB9A | |
| SCHEMBL6286276 | 0.78 | SMN1; SMN2 (0.44) | CLK1KDM4EALDH1A1HPGDPKM | |
| SCHEMBL6737035 | 0.78 | RXFP1 (0.46) | CLK1KDM4EALDH1A1HPGDPKM | |
| SCHEMBL6283845 | 0.75 | KCNH2 (0.53) | ALDH1A1RXFP1NPC1RAB9A | |
| SCHEMBL6284361 | 0.74 | RXFP1 (0.57) | ALDH1A1RXFP1SMN1; SMN2 | |
| SCHEMBL17808808 | 0.73 | MAPT (0.63) | KDM4EALDH1A1HPGDPKMRXFP1 | |
| SCHEMBL6288980 | 0.73 | RXFP1 (0.47) | KDM4EALDH1A1HPGDRXFP1HSD17B10 | |
| SCHEMBL14162062 | 0.72 | KDM4E (0.62) | KDM4EALDH1A1HPGDPKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903097-B2 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | disclosed |
| US-6559145-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | CLK1 4453/4885KDM4E 201/4885ALDH1A1 779/4885 |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | CLK1 4453/4885KDM4E 201/4885ALDH1A1 779/4885 |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | CLK1 4453/4885KDM4E 201/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.